Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy

Journal of Viral Hepatitis

Volumn 21, Issue 4, 2014, Pages 288-296

  Hafkin, J S ^a,b,c   Osborn, M K ^d   Localio, A R ^b   Amorosa, V K ^a,c   Kostman, J R ^a,e   Stern, J J ^a,f   De La Torre, P ^g   Mounzer, K ^a,h   Frank, I ^a   Gross, R ^a,b,c   Chang, K M ^b,c   Lo Re, V ^a,b,c,e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^f PENNSYLVANIA HOSPITAL   (United States)

^g Division of Female Pelvic Medicine and Reconstructive Surgery   (United States)

^h Philadelphia Field Initiating Group for HIV 1 Trials   (United States)

Author keywords

hepatitis B virus; HIV; HIV hepatitis B virus co infection; lamivudine; tenofovir

Indexed keywords

EMTRICITABINE; LAMIVUDINE; TENOFOVIR; VIRUS DNA; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; VIREMIA;

HEPATITIS B VIRUS; HIV; HIV/HEPATITIS B VIRUS CO-INFECTION; LAMIVUDINE; TENOFOVIR;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; COINFECTION; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; INCIDENCE; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RETROSPECTIVE STUDIES; RISK FACTORS; VIRAL LOAD; VIREMIA;

EID: 84895798776     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12142     Document Type: Article

References (46)

1. Alter MJ,. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44 (Suppl. 1): S6-S9.
2. Thio CL, Seaberg EC, Skolasky R Jr, et al,. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360 (9349): 1921-1926.
3. Konopnicki D, Mocroft A, de Wit S, et al,. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19 (6): 593-601.
4. Weber R, Sabin CA, Friis-Moller N, et al,. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166 (15): 1632-1641.
5. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Edited by DHHS: Panel on Antiretroviral Guidelines for Adults and Adolescents; March 27, 2012.
6. Thompson MA, Aberg JA, Cahn P, et al,. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304 (3): 321-333.
7. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ,. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130 (3): 678-686.
8. Pungpapong S, Kim WR, Poterucha JJ,. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc 2007; 82 (8): 967-975.
9. Chen CJ, Yang HI, Su J, et al,. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295 (1): 65-73.
10. Puoti M, Torti C, Bruno R, Filice G, Carosi G,. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006; 44 (Suppl. 1): S65-S70.
11. Lok AS, McMahon BJ,. Chronic hepatitis B. Hepatology 2007; 45 (2): 507-539.
12. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50 (3): 661-662.
13. Liaw YF, Leung N, Kao JH, et al,. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2 (3): 263-283.
14. Lai CL, Yuen MF,. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 2007; 147 (1): 58-61.
15. Soriano V, Tuma P, Vispo E, et al,. Hepatitis B in HIV patients: what is the current treatment and what are the challenges? J HIV Ther 2009; 14 (1): 13-18.
16. Iser DM, Sasadeusz JJ,. Current treatment of HIV/hepatitis B virus coinfection. J Gastroenterol Hepatol 2008; 23 (5): 699-706.
17. Soriano V, Puoti M, Bonacini M, et al,. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 2005; 19 (3): 221-240.
18. Soriano V, Puoti M, Peters M, et al,. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 2008; 22 (12): 1399-1410.
19. Bhattacharya D, Thio CL,. Review of hepatitis B therapeutics. Clin Infect Dis 2010; 51 (10): 1201-1208.
20. Dore GJ, Soriano V, Rockstroh J, et al,. Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. AIDS 2010; 24 (6): 857-865.
21. Keeffe EB, Dieterich DT, Han SH, et al,. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6 (12): 1315-1341; quiz 1286.
22. Ratcliffe L, Beadsworth MB, Pennell A, Phillips M, Vilar FJ,. Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients. AIDS 2011; 25 (8): 1051-1056.
23. Valsamakis A,. Molecular testing in the diagnosis and management of chronic hepatitis B. Clin Microbiol Rev 2007; 20 (3): 426-439, table of contents.
24. Shyamala V, Arcangel P, Cottrell J, et al,. Assessment of the target-capture PCR hepatitis B virus (HBV) DNA quantitative assay and comparison with commercial HBV DNA quantitative assays. J Clin Microbiol 2004; 42 (11): 5199-5204.
25. Zoulim F, Durantel D, Deny P,. Management and prevention of drug resistance in chronic hepatitis B. Liver Int 2009; 29 (Suppl. 1): 108-115.
26. Zoulim F, Locarnini S,. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137 (5): 1593-1608, e1591-1592.
27. Matthews GV, Avihingsanon A, Lewin SR, et al,. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 2008; 48 (4): 1062-1069.
28. Royston P,. Multiple imputation of missing values: update. Stata J 2005; 5 (2): 188-201.
29. Rubin DB,. Multiple Imputation for Nonresponse in Surveys. New York: John Wiley & Sons, 2004.
30. Gross R, Bilker WB, Friedman HM, Strom BL,. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 2001; 15 (16): 2109-2117.
31. Peters MG, Andersen J, Lynch P, et al,. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006; 44 (5): 1110-1116.
32. Jain MK, Comanor L, White C, et al,. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. J Viral Hepat 2007; 14 (3): 176-182.
33. Benhamou Y, Fleury H, Trimoulet P, et al,. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006; 43 (3): 548-555.
34. Lacombe K, Gozlan J, Boelle PY, et al,. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. AIDS 2005; 19 (9): 907-915.
35. Stephan C, Berger A, Carlebach A, et al,. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. J Antimicrob Chemother 2005; 56 (6): 1087-1093.
36. Engell CA, Pham VP, Holzman RS, Aberg JA,. Virologic outcome of using tenofovir/emtricitabine to treat Hepatitis B in HIV-coinfected patients. ISRN Gastroenterol 2011; 2011: 405390.
37. Lada O, Gervais A, Branger M, et al,. Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G. Liver Int 2012; 32 (1): 93-101.
38. Piroth L, Pol S, Lacombe K, et al,. Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study. J Hepatol 2010; 53 (6): 1006-1012.
39. de Vries-Sluijs TE, Reijnders JG, Hansen BE, et al,. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology 2010; 139 (6): 1934-1941.
40. Cohen CJ, Andrade-Villanueva J, Clotet B, et al,. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378 (9787): 229-237.
41. Wong GL, Chan HL,. Predictors of treatment response in chronic hepatitis B. Drugs 2009; 69 (16): 2167-2177.
42. Wang FS, Zhang Z,. Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus. Expert Rev Gastroenterol Hepatol 2009; 3 (5): 499-512.
43. Lacombe K,. HBV Blippers and Rebounders under Treatment with Tenofovir in HIV/HBV Co-infection. In 16th Conference on Retroviruses and Opportunistic infections. 2010.
44. Maylin S, Boyd A, Lavocat F, et al,. Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients. AIDS 2012; 26 (8): 939-949.
45. Chun HM, Fieberg AM, Hullsiek KH, et al,. Epidemiology of Hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years. Clin Infect Dis 2010; 50 (3): 426-436.
46. Kellerman SE, Hanson DL, McNaghten AD, Fleming PL,. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188 (4): 571-577.